Incyte study could bring lessons for cancer immunotherapy

06:00 EDT 14 Mar 2018 | BioPharmaDive

Merck has bet on the potential of Incyte's IDO inhibitor as a partner for Keytruda across five different cancer types. A Phase 3 trial in melanoma is first up.

Original Article: Incyte study could bring lessons for cancer immunotherapy


More From BioPortfolio on "Incyte study could bring lessons for cancer immunotherapy"

Quick Search


Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...